US Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 190% Upside Potential Amidst Challenging Financials

Vir Biotechnology, Inc. (NASDAQ: VIR) is generating buzz in the healthcare sector, particularly in biotechnology, with an enticing potential upside of 190.43%. As a clinical-stage biopharmaceutical company, Vir focuses on..

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Sector with a Unique Market Position

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, is capturing investor attention with its innovative approaches and strategic market positioning. Based in Stayner, Canada, Cronos is..

Xeris Biopharma Holdings, Inc. (XERS)

⚠️ No article content returned.

..

Valneva SE (VALN) Stock Analysis: Exploring the 58% Upside Potential in the Biotech Sector

Valneva SE (VALN), a French biotechnology company, is capturing the attention of investors with its ambitious vaccine portfolio focused on infectious diseases with unmet needs. As the healthcare sector continues..

Talkspace, Inc. (TALK) Investor Outlook: A Healthcare Disruptor with 34.92% Potential Upside

Talkspace, Inc. (NASDAQ: TALK) is making waves in the healthcare sector with its innovative approach to mental health services. As a virtual behavioral healthcare company, Talkspace connects patients with licensed..

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a Potential 178% Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a key player in the biotechnology sector, has caught the attention of investors with its promising potential upside of 178.56%. As a Canadian company specializing..

Keros Therapeutics, Inc. (KROS) Investor Outlook: A 16% Upside Potential with Robust Revenue Growth

Keros Therapeutics, Inc. (NASDAQ: KROS), a burgeoning player in the biotechnology sector, has been capturing investor attention with its impressive revenue growth and promising pipeline of therapeutics. With a market..

Replimune Group, Inc. (REPL) Stock Analysis: Unveiling the 29.74% Potential Upside in Biotech

Replimune Group, Inc. (NASDAQ: REPL) is emerging as a compelling player in the biotechnology sector, capturing investor attention with its innovative approach to cancer treatment through oncolytic immunotherapies. With a..

Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Gem with 29% Upside Potential

Investors with a keen eye on the biotechnology sector may find Cogent Biosciences, Inc. (NASDAQ: COGT) particularly intriguing. With a market capitalization of $5.82 billion, the Massachusetts-based company is carving..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating a 55.66% Potential Upside in Biotech

For investors with an eye on the biotechnology sector, Praxis Precision Medicines, Inc (NASDAQ: PRAX) presents an intriguing opportunity. With a market capitalization of $6.73 billion, this Boston-based clinical-stage biopharmaceutical..

KalVista Pharmaceuticals, Inc. (KALV): Analyst Consensus Reveals Over 100% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a burgeoning name in the biotechnology sector, is capturing investor attention with its innovative approach to addressing unmet medical needs. Specializing in the discovery and..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a 217.58% Potential Upside

Bicycle Therapeutics plc (BCYC), a UK-based biotechnology firm, is making waves in the healthcare sector with its innovative therapeutic solutions aimed at addressing diseases lacking effective treatments. With a market..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 239% Upside Potential in Innovative Cancer Therapies

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company at the forefront of biotechnology, is capturing the attention of investors with its promising therapies targeting metastatic melanoma and other solid tumors. With..

Eton Pharmaceuticals (ETON) Investor Outlook: Exploring an 87% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing investor attention with its robust growth potential in the niche market of rare disease treatments. With a market capitalization of $429.62 million, this..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unpacking the 84.65% Potential Upside for Investors

In the ever-evolving landscape of biotechnology, Bicara Therapeutics Inc. (NASDAQ: BCAX) emerges as a compelling player with substantial growth potential. With a market capitalization of $966.35 million, this clinical-stage biopharmaceutical..

GH Research PLC (GHRS) Stock Analysis: Exploring a 138.80% Upside in the Biotech Sector

GH Research PLC (NASDAQ: GHRS), a Dublin-based biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to treating depression. The company’s focus on developing novel treatments..

Xencor, Inc. (XNCR) Investor Outlook: An 80% Upside Potential in the Biotech Frontier

Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company based in Pasadena, California, is capturing the attention of investors with a potential upside of 80.05%, according to current analyst ratings. With a..

Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside of Over 90% Beckons Investors

Pharvaris N.V. (PHVS), a biopharmaceutical entity based in Zug, Switzerland, is making waves in the healthcare sector with its pioneering approach to treating rare diseases such as hereditary angioedema (HAE)...

Sionna Therapeutics, Inc. (SION) Stock Analysis: Strong Buy Ratings Amidst Promising Cystic Fibrosis Pipeline

Sionna Therapeutics, Inc. (SION), a burgeoning player in the biotechnology sector, has captured the attention of investors with its promising pipeline focused on cystic fibrosis treatments. Despite the challenges typical..

Embecta Corp. (EMBC) Stock Analysis: Exploring a 42% Potential Upside in the Healthcare Sector

Embecta Corp. (NASDAQ: EMBC), a prominent player in the healthcare sector, specializes in medical instruments and supplies, focusing on diabetes management solutions. Despite operating in a challenging market, Embecta presents..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds